Epirubicin Hydrochloride (Mayne Pharma) is a medicine containing the active ingredient(s) epirubicin. On this page you will find out more about Epirubicin Hydrochloride (Mayne Pharma), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: epirubicin
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Epirubicin Hydrochloride (Mayne Pharma) 50 mg/25 mL injection solution, 25 mL vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic disease. DBL Epirubicin Hydrochloride Injection and DBL Epirubicin Hydrochloride for Injection are indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-Hodgkin's lymphoma), advanced/metastatic soft tissue sarcoma and superficial bladder cancer (Tis; Ta). In bladder cancer, DBL Epirubicin Hydrochloride Injection and DBL Epirubicin Hydrochloride for Injection are also indicated in the prophylaxis of recurrence after transurethral resection of T1 papillary cancers and stage Ta multifocal papillary cancers (Grade 2 and 3).
Table of characteristics
|Visual appearance||A clear, red solution free from visible particulates|
|Dosage Form||Injection, solution|
|Route of administration||Intravenous|
undefined: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.